For roughly twenty years, if a hospital wanted a robot capable of soft-tissue surgery — the kind used in general, gynecologic, and urologic procedures — there was really one vendor to call: Intuitive Surgical, maker of the da Vinci system. That changed on July 22, 2026, when the FDA granted Johnson & Johnson’s Ottava system De Novo authorization, a regulatory pathway used to establish an entirely new device classification rather than simply clearing a device as equivalent to something already on the market. The clearance covers a specific slate of general surgery procedures — including Roux-en-Y gastric bypass, gastric sleeve surgery, and appendectomy — and J&J is marketing Ottava as the first table-integrated soft-tissue robotic system, meaning the robotic arms are built directly into the operating table rather than standing as separate equipment wheeled into the room.
The clearance caps a genuinely long bet: J&J has spent roughly a decade and multiple billions of dollars developing Ottava, after acquiring surgical robotics assets and folding them into its Ethicon and J&J MedTech divisions. It’s not the first credible challenger to reach the market — Medtronic’s Hugo system cleared FDA review for urologic procedures back in December 2025, with its first commercial case performed at Cleveland Clinic in February 2026 — but Ottava’s broader general-surgery clearance and table-integrated design make it the most direct competitive threat Intuitive Surgical has faced since da Vinci first launched.
The Incumbent’s Advantage Isn’t the Robot — It’s the Installed Base
The scale gap between challenger and incumbent is still enormous. Intuitive Surgical shipped roughly 350 da Vinci systems in the second quarter of 2026 alone — a single quarter’s shipments larger than most young medtech companies’ cumulative sales. Every one of those installations comes with surgeons trained specifically on da Vinci’s interface, hospital service contracts, instrument supply chains, and — critically — the kind of clinical outcome data built up over two decades that makes hospital procurement committees comfortable signing off on a purchase that can run into the millions of dollars once installation, training, and service contracts are included. A newly cleared competitor doesn’t erase any of that on day one. What the clearance actually does is give hospital systems negotiating leverage they haven’t had before: for the first time, a health system evaluating a robotic surgery purchase can credibly threaten to walk to a competitor, which historically has been the single biggest lever for bringing down capital equipment and service pricing in any medical device category.
A Genuinely Competitive Market Changes What Gets Built Next
With Medtronic’s Hugo and now J&J’s Ottava both cleared, soft-tissue robotic surgery moves from a single-vendor market to a genuinely competitive one for the first time since the category existed — which tends to accelerate feature development and pricing pressure in ways a monopoly never does. It also validates a broader thesis several other medtech robotics companies are betting on: Zeta Surgical’s TMS robotic targeting system and Momentis’s Anovo multiport platform both cleared FDA review within days of the Ottava news, suggesting the surgical robotics category as a whole is moving past its single-dominant-player phase across several specialties at once, not just general surgery.
What This Means for Philippine Founders
Robotic surgery has historically been out of reach for most Philippine hospitals — a single da Vinci system can cost well over a million dollars before service contracts and per-procedure instrument costs, which has largely confined the technology to a small number of private hospitals serving medical tourism and premium domestic patients. A genuinely competitive market between J&J, Medtronic, and Intuitive Surgical is the single most likely force to bring that price down over the next several years, the same way competition eventually did for CT and MRI equipment. That matters directly for Philippine health-tech and medical-device distribution startups: a market where hospitals can negotiate between three credible vendors instead of accepting one is also a market where local distribution, financing, and after-sales service partnerships become more valuable and more contestable than when a single company controlled the entire category. For founders building surgical training, telemonitoring, or hospital procurement software, three real robotic-surgery platforms — each with its own interface and data format — instead of one is also a more interesting integration problem than it was a year ago.
Share this article